BK1261 Pharmaceutical Outsourcing/contract Research Organization(cro Concept)
- 480.896
- +24.369+5.34%
Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2%
Pharmaron Beijing Co (HKG:3759) reported a profit attributable to owners of 230.6 million yuan for the quarter ended March 31, 2024, down 33.8% from 348.3 million yuan in the previous year, according
藥明康德：2023年度報告
Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy
04:44 AM EDT, 04/26/2024 (MT Newswires) -- Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy Price (RMB): ¥80.99, Change: ¥+4.13, Percent Change: +5.37%
Minsheng Securities released a research report on April 26 stating that Kanglong Chemical (300759.SZ) was given a recommended rating. The main reasons for the rating include: 1) laboratory services are recovering month-on-month, and new orders for small m
Minsheng Securities released a research report on April 26 stating that Kanglong Chemical (300759.SZ) was given a recommended rating. The main reasons for the rating include: 1) laboratory services are recovering month-on-month, and new orders for small molecule CDMO are growing rapidly; 2) the clinical research business is progressing steadily, and the macromolecule and CGT sectors are under pressure in the short term; 3) the increase in customer demand sends a positive signal of recovery, keeping the growth guide unchanged throughout the year. (Mainichi Keizai Shimbun)
On April 26, Yao Ming Kangde (02359.HK) spent 2005 million yuan to buy back 475,500 A shares
Gelonghui, April 26, 丨 Yao Ming Kangde (02359.HK) issued an announcement. On April 26, 2024, it spent RMB 2005 million yuan to buy back 475,500 A shares, with a repurchase price of 41.32-43.11 yuan per share.
Yao Ming Kangde (02359) spent 2.047,800 yuan to buy back 475,500 A shares on April 26
Yao Ming Kangde (02359) announced that on April 26, 2024, the company spent 2.047,800 yuan to buy back 475,500 A-shares.
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy
04:40 AM EDT, 04/26/2024 (MT Newswires) -- Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy Price (HKD): $9.48, Change: $+0.68, Percent Change: +7.73%
維亞生物：2023年度報告
A quick look at the Hong Kong market | Hong Kong stocks explode! The Ke Index rose nearly 5%; domestic housing stocks and auto stocks improved, Sunac China rose more than 15%, and Xiaopeng Motors rose nearly 9%
Technet stocks performed brilliantly. Kuaishou rose more than 7%, JD rose nearly 6%; biotech stocks generally rose, Tiger Pharmaceuticals rose more than 8%, and Pharmaceutical Biotech rose nearly 6%.
Pharmaron Beijing To Repurchase Shares Worth Up To 300 Million Yuan; Shares Jump 8%
Pharmaron Beijing (HKG:3759) plans to repurchase shares worth 200 million to 300 million yuan from the Shenzhen Stock Exchange through bidding, according to a Thursday filing on the Hong Kong bourse.
Changes in Hong Kong stocks | Tiger Pharmaceuticals (03347) rose more than 8% to lead CRO concept stocks, reports say the national level is expected to introduce an action plan for the biological manufacturing industry in the near future
CRO concept stocks increased their gains in the afternoon. As of press release, Tiger Pharmaceuticals (03347) rose 8.39% to HK$33.6; Kanglong Chemical (03759) rose 7.16% to HK$9.43; Pharmaceutical Biotech (02269) rose 6.75% to HK$13.6; and Pharmaceuticals (02359) rose 4.74% to HK$35.35.
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.
Minsheng Securities released a research report on April 26 stating that it gave Gloria Ying (002821.SZ) a recommended rating. The main reasons for the rating include: 1) rapid revenue growth in the European and American markets, and continued deepening se
Minsheng Securities released a research report on April 26 stating that it gave Gloria Ying (002821.SZ) a recommended rating. The main reasons for the rating include: 1) rapid revenue growth in the European and American markets, and continued deepening service to multinational pharmaceutical companies and overseas customers; 2) the steady growth of small-molecule CDMOs and the acceleration of platform layout and customer promotion in emerging businesses. (Mainichi Keizai Shimbun)
April 25 Repurchase Collection | Hang Seng Bank, Swire Group A and others bought back one after another. Of these, Hang Seng Bank spent HK$61.109 million
According to documents disclosed by the Hong Kong Stock Exchange on April 26, $Hang Seng Bank (00011.HK) $ and $Swire Group A (00019.HK) $ repurchased shares. ① $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 25, involving an amount of HK$61.1091 million. The repurchase price per share ranged from HK$102.3 to HK$100.1. The cumulative number of securities repurchased during the year (since the adoption of the ordinary resolution) is 5.714 million shares, accounting for 0.299% of the number of shares issued when the ordinary resolution was passed. ② $
Statistics on changes in the share of Zhitong Hong Kong Stock Connect | April 26
According to data disclosed on April 25, 2024, Shengnuo Pharmaceutical-B (02257.HK), Tiger Pharmaceuticals (03347.HK), and Peer Hunting (06100.HK) Hong Kong Stock Connect held the largest share value added, increasing 0.58%, 0.47%, and 0.39% respectively; China Alcoa International (02068.HK), Luoyang Yiye (03993.HK), and Country Garden Services (06098.HK) had the largest share losses, decreasing -0.0.75%, -0.3%, respectively -0.57%.
Will Weakness in WuXi AppTec Co., Ltd.'s (SHSE:603259) Stock Prove Temporary Given Strong Fundamentals?
WuXi AppTec (SHSE:603259) has had a rough three months with its share price down 37%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually d
Featured announcements | CNOOC's net profit for the first quarter was nearly 40 billion yuan; China Aluminum's net profit for the first quarter increased 23.01% year-on-year
ZTE's net profit for the first quarter increased by 3.74% year on year; Times Electric's net profit for the first quarter increased by 30.44% year on year.
Pharmaron Beijing: Committed to Supporting Partners' Success in Discovery, Development, Commercialization of Innovative Medicines >300759.SZ
Pharmaron Beijing: Committed to Supporting Partners' Success in Discovery, Development, Commercialization of Innovative Medicines >300759.SZ
Pharmaron Beijing: Revenue Temporarily Fell in 1Q Partly Due to Slowdown of Growth in Customer Demand >300759.SZ
Pharmaron Beijing: Revenue Temporarily Fell in 1Q Partly Due to Slowdown of Growth in Customer Demand >300759.SZ
Pharmaron Beijing 1Q Rev CNY2.67B Vs. CNY2.72B >300759.SZ
Pharmaron Beijing 1Q Rev CNY2.67B Vs. CNY2.72B >300759.SZ